Pembrolizumab
| Subclass of | chemical compound  |
|---|---|
| Get use | Medication |
| Active ingredient in | Keytruda |
| World Health Organisation international non-proprietary name | pembrolizumab |
| Physically dey interact plus | programmed cell death 1 |
| Route of administration | intravenous infusion and defusion |
| LiverTox likelihood score | LiverTox toxicity likelihood category E* |
| Get characteristic | biopharmaceutical |
| Subject has role | immunological antineoplastic agent, monoclonal antibody |
Pembrolizumab, dem sell under de brand name Keytruda, be a humanized monoclonal antibody, more specifically a PD-1 inhibitor, dem use insyd cancer immunotherapy to treat chaw types of cancer.[1][2] E be administered by slow intravenous injection.[2]
Common side effects dey include fatigue, musculoskeletal pain, decreased appetite, itchy skin, diarrhea, nausea, rash, fever, cough, difficulty breathing, constipation, pain, den abdominal pain.[2][3] E be an IgG4 isotype antibody wey dey block a protective mechanism of cancer cells, wey dey allow de immune system to destroy dem. E dey target de programmed cell death protein 1 (PD-1) receptor of lymphocytes.[3]
Dem approve pembrolizumab for medical use insyd de United States insyd 2014.[2][4] E dey on de World Health Organization's List of Essential Medicines.[5] Na dem approve a fixed-dose combination of pembrolizumab den berahyaluronidase alfa, (Keytruda Qlex) for medical use insyd de United States insyd September 2025.[6][7]
References
[edit | edit source]- ↑ "Keytruda- pembrolizumab injection, powder, lyophilized, for solution Keytruda- pembrolizumab injection, solution". DailyMed. 17 September 2019. Archived from the original on 17 June 2020. Retrieved 10 January 2020.
- 1 2 3 4 "Pembrolizumab Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 14 June 2020. Retrieved 15 July 2019.
- 1 2 "FDA Approves First-Line Immunotherapy for Patients with MSI-H/dMMR Metastatic Colorectal Cancer" (Press release). U.S. Food and Drug Administration (FDA). 29 June 2020. Archived from the original on 29 June 2020. Retrieved 29 June 2020.
- ↑ "Drug Approval Package: Keytruda (pembrolizumab) Powder for Injection NDA #125514". U.S. Food and Drug Administration (FDA). 2 October 2014. Retrieved 21 September 2025.
- ↑ The selection and use of essential medicines, 2025: WHO Model List of Essential Medicines, 24th list. Geneva: World Health Organization. 2025. doi:10.2471/B09474. hdl:10665/382243. License: CC BY-NC-SA 3.0 IGO.
- ↑ "FDA approves pembrolizumab and berahyaluronidase alfa-pmph". U.S. Food and Drug Administration (FDA). 19 September 2025. Retrieved 21 September 2025.
- ↑ "FDA Approves Merck's Keytruda Qlex (pembrolizumab and berahyaluronidase alfa-pmph) Injection for Subcutaneous Use in Adults Across Most Solid Tumor Indications for Keytruda (pembrolizumab)". Merck (Press release). 21 September 2025. Retrieved 21 September 2025.
Read further
[edit | edit source]- Kang SP, Gergich K, Lubiniecki GM, de Alwis DP, Chen C, Tice MA, Rubin EH (June 2017). "Pembrolizumab KEYNOTE-001: an adaptive study leading to accelerated approval for two indications and a companion diagnostic". Annals of Oncology. 28 (6): 1388–1398. doi:10.1093/annonc/mdx076. PMC 5452070. PMID 30052728.
External links
[edit | edit source]
- "Pembrolizumab". National Cancer Institute. 18 September 2014.
- Pembrolizumab at the U.S. National Library of Medicine Medical Subject Headings (MeSH)